45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
11,990
Insurances with rates
8
CPT / HCPCS codes
10,938
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $75,601 | $192,797 | $192,797 | 1 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $75,601 | $166 | $192,797 | 19 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $41,092 | $104,792 | $104,792 | 1 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $41,092 | $53.42 | $104,792 | 19 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $39,542 | $100,840 | $100,840 | 1 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $39,542 | $126 | $100,840 | 19 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $36,732 | $93,674 | $93,674 | 1 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $36,732 | $123 | $93,674 | 19 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $28,586 | $72,901 | $72,901 | 1 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $28,586 | $141 | $72,901 | 19 |
| 33270 | HC INS/REP SUBC DEFIBRILLATOR | $72,970 | $26,038 | $66,403 | $66,403 | 1 |
| 33270 | HC INS/REP SUBC DEFIBRILLATOR | $72,970 | $26,038 | $10,420 | $66,403 | 17 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $23,772 | $60,623 | $60,623 | 1 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $23,772 | $230 | $60,623 | 19 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $23,234 | $59,251 | $59,251 | 1 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $23,234 | $82.46 | $59,251 | 19 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $22,673 | $57,820 | $57,820 | 1 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $22,673 | $26 | $57,820 | 19 |
| 33249 | HC INSERT ICD+LEAD SNGL/DUAL | $61,672 | $22,007 | $56,122 | $56,122 | 1 |
| 33249 | HC INSERT ICD+LEAD SNGL/DUAL | $61,672 | $22,007 | $8,807 | $58,090 | 17 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $20,632 | $52,616 | $52,616 | 1 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $20,632 | $97.71 | $52,616 | 19 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $20,496 | $52,270 | $52,270 | 1 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $20,496 | $48.97 | $52,270 | 19 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $19,837 | $50,587 | $50,587 | 1 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $19,837 | $7,938 | $50,587 | 10 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $18,657 | $47,579 | $47,579 | 1 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $18,657 | $84.52 | $47,579 | 19 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $17,872 | $45,577 | $45,577 | 1 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $17,872 | $19.55 | $45,577 | 19 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $49,250 | $17,574 | $44,818 | $44,818 | 1 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $49,250 | $17,574 | $7,033 | $44,818 | 10 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $49,250 | $17,574 | $44,818 | $44,818 | 1 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $49,250 | $17,574 | $7,033 | $44,818 | 10 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $49,250 | $17,574 | $44,818 | $44,818 | 1 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $49,250 | $17,574 | $7,033 | $44,818 | 10 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $49,250 | $17,574 | $44,818 | $44,818 | 1 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $49,250 | $17,574 | $7,033 | $44,818 | 10 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $49,250 | $17,574 | $44,818 | $44,818 | 1 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $49,250 | $17,574 | $7,033 | $44,818 | 10 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $49,250 | $17,574 | $44,818 | $44,818 | 1 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $49,250 | $17,574 | $7,033 | $44,818 | 10 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $48,444 | $17,286 | $44,084 | $44,084 | 1 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $48,444 | $17,286 | $33.21 | $44,084 | 19 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $17,041 | $43,458 | $43,458 | 1 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $17,041 | $187 | $43,458 | 19 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $16,922 | $43,155 | $43,155 | 1 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $16,922 | $69.5 | $43,155 | 19 |
| 33264 | HC REMOVAL&REPL ICD GN MULT LD | $46,720 | $16,671 | $42,515 | $42,515 | 1 |
| 33264 | HC REMOVAL&REPL ICD GN MULT LD | $46,720 | $16,671 | $6,672 | $58,090 | 17 |
Showing top 50 of 11,990 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.